Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. Summary
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
2.67(c) 2.5201(c) 2.5(c) 2.4(c) 2.3(c) Last
70 017 107 073 157 398 69 493 138 753 Volume
+1.52% -5.61% -0.80% -4.00% -4.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 23,7 M - -
Net income 2021 -13,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,69x
Yield 2021 -
Sales 2022 24,9 M - -
Net income 2022 -11,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,56x
Yield 2022 -
Capitalization 62,7 M 62,7 M -
Capi. / Sales 2021 2,65x
Capi. / Sales 2022 2,51x
Nbr of Employees -
Free-Float 57,2%
More Financials
Company
MediWound Ltd. is a Israel-based biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and... 
Sector
Pharmaceuticals
Calendar
01/05Presentation
More about the company
Ratings of MediWound Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MEDIWOUND LTD.
05:46aMediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study, Topl..
AQ
12/06MediWound Completes Enrollment of Phase 2 Study of EscharEx; Shares Rise Pre-Bell
MT
12/06MEDIWOUND : Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study - Form..
PU
12/06MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
AQ
11/18EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
GL
11/16MEDIWOUND : Q3 Earnings Snapshot
AQ
11/16MEDIWOUND : Reports Third Quarter 2021 Financial Results - Form 6-K
PU
11/16MediWound Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/16MediWound Reports Third Quarter 2021 Financial Results
AQ
11/16Earnings Flash (MDWD) MEDIWOUND Posts Q3 Revenue $6.4M, vs. Street Est of $5.67M
MT
11/04MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and..
GL
10/04MEDIWOUND : Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparato..
GL
09/06MEDIWOUND : to Present at Upcoming Investor Conferences
AQ
09/03MediWound to Present at Upcoming Investor Conferences
GL
08/10MEDIWOUND : Q2 Earnings Snapshot
AQ
More news
News in other languages on MEDIWOUND LTD.
12/06MediWound achève le recrutement de l'étude de phase 2 sur EscharEx ; les actions augmen..
11/16Earnings Flash (MDWD) MEDIWOUND affiche un chiffre d'affaires de 6,4 millions de dollar..
08/10Earnings Flash (MDWD) MEDIWOUND affiche un chiffre d'affaires de 6,1 millions de dollar..
06/29MediWound déclare que la demande de licence biologique de NexoBrid pour l'ablation des ..
06/09MediWound atteint l'objectif de recrutement de patients pour l'évaluation intermédiaire..
More news
Analyst Recommendations on MEDIWOUND LTD.
More recommendations
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,30 $
Average target price 6,92 $
Spread / Average Target 201%
EPS Revisions
Managers and Directors
Sharon Malka Chief Executive Officer
Boaz Gur-Lavie Chief Financial Officer
Stephen T. Wills Executive Chairman
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDIWOUND LTD.-37.84%63
CSL LIMITED4.63%95 165
WUXI BIOLOGICS (CAYMAN) INC.-6.71%52 197
SAMSUNG BIOLOGICS CO.,LTD.9.08%50 476
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.55%32 920